prikaz prve stranice dokumenta What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
  Preuzmi
PDF 4.89 MB
Znanstveni rad - Izvorni znanstveni rad
What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
Human Vaccines & Immunotherapeutics, 19 (2023), 3; 2270310. https://doi.org/10.1080/21645515.2023.2270310
Ravlić, Sanda; Kurtović, Tihana; Cvetko Krajinović, Lidija; Hećimović, Ana; Miloš, Marija; Mateljak Lukačević, Sanja; Markotić, Alemka; Halassy, Beata

Citirajte ovaj rad

Ravlić, S., Kurtović, T., Cvetko Krajinović, L., Hećimović, A., Miloš, M., Mateljak Lukačević, S. ... Halassy, B. (2023). What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?. Human Vaccines & Immunotherapeutics, 19. (3). doi: 10.1080/21645515.2023.2270310

Ravlić, Sanda, et al. "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?." Human Vaccines & Immunotherapeutics, vol. 19, br. 3, 2023. https://doi.org/10.1080/21645515.2023.2270310

Ravlić, Sanda, Tihana Kurtović, Lidija Cvetko Krajinović, Ana Hećimović, Marija Miloš, Sanja Mateljak Lukačević, Alemka Markotić i Beata Halassy. "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?." Human Vaccines & Immunotherapeutics 19, br. 3 (2023). https://doi.org/10.1080/21645515.2023.2270310

Ravlić, S., et al. (2023) 'What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?', Human Vaccines & Immunotherapeutics, 19(3). doi: 10.1080/21645515.2023.2270310

Ravlić S, Kurtović T, Cvetko Krajinović L, Hećimović A, Miloš M, Mateljak Lukačević S, i sur.. What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?. Human Vaccines & Immunotherapeutics [Internet]. 31.10.2023. [pristupljeno 21.10.2024.];19(3). doi: 10.1080/21645515.2023.2270310

S. Ravlić, et al., "What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?", Human Vaccines & Immunotherapeutics, vol. 19, br. 3, Listopad 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:749533. [Citirano: 21.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:749533
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?
AutorSanda Ravlić
AutorTihana Kurtović
AutorLidija Cvetko Krajinović
AutorAna Hećimović
AutorMarija Miloš
AutorSanja Mateljak Lukačević
AutorAlemka Markotić
AutorBeata Halassy
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
In the COVID-19 pandemic, we have witnessed an impressive speed in the development of effective vaccines approved for human use, based on clinical studies comparing their efficacy to placebo. A head-to-head comparison of the neutralizing antibody (NAb) responses elicited by four vaccines used in Europe during 2021 (BNT162b2, mRNA-1273, ChAdOx nCoV-19, Ad26.COV2.S) and their comparison to NAb responses in convalescents showed that while the amount was comparable, NAbs induced by natural infection were of superior quality. The highly scattered immune responses elicited by the four vaccines were equalled by booster mRNA vaccination, reaching the highest, plateau level of NAb at the population level. Equally high NAbs were induced in convalescents after a single injection of either vaccine. The use of wild-type virus as a challenge in the NAb determination revealed that NAbs produced by disease were better activators of the complement system than NAbs induced by vaccination. The contribution of spike protein-specific IgGs to the SARS-CoV-2 neutralization was lower in convalescents compared to vaccinees, indicating that those who recovered from COVID-19 were armed with antibodies of additional specificities and/or classes that contributed to virus neutralization. Such findings point to the need to re-examine the correctness of certain epidemiological measures applied in the current epidemic. We also highlight the importance of a standardized approach in assessing humoral immunity by the usage of the most comprehensive assays as early as possible in future epidemics.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHuman Vaccines & Immunotherapeutics
Brojčani podacivol. 19, br. 3, 2270310
p-ISSN2164-5515
e-ISSN2164-554X
DOIhttps://doi.org/10.1080/21645515.2023.2270310
URN:NBNurn:nbn:hr:184:749533
Datum objave publikacije2023-10-31
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
ProjektŠifra: KK.011.1.01.0006
Naziv (hrvatski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: ERDF
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/21645515.2023.2270310
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-31 09:35:06